⸺ Synova Research
CGRI
Long-acting amylin analogue researched for appetite regulation and weight management, often paired with GLP-1 agonists in metabolic studies.
Secure checkout via UK open banking. Free shipping on orders over £100.
Independently tested
COA on request
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
- • Peptides sold in lyophilized form
- • Strictly for laboratory research
⸺ Overview
About CGRI
CGRI is a synthetic long-acting analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Researchers investigate it for satiety signalling, slowed gastric emptying and combined effects when paired with GLP-1 receptor agonists such as SMGT or RTTA.
⸺ Mechanism of Action
How it works
CGRI acts on amylin and calcitonin receptors in the central nervous system, modulating satiety and gastric motility. In animal studies, this produces reduced food intake and changes in body composition, with additive effects observed alongside incretin agonists.
⸺ Research
Areas of study
Appetite signalling
Rodent studies demonstrate reduced food intake via central amylin-receptor pathways, with effects sustained over chronic dosing.
Combination with GLP-1 agonists
Preclinical work pairing CGRI with GLP-1 receptor agonists reports additive effects on body weight and glycaemic markers.
Gastric emptying
Animal models show slower gastric emptying, supporting hypotheses around prolonged satiety following meals.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details
Specification
- CAS
- 1415456-99-3
- Intended use
- Research use only.
- Storage
- Lyophilised: cool, dry, away from sunlight. Reconstituted: refrigerate at 2–8°C.
- Solubility
- Vial holds up to 3mL.
- Shelf life
- Lyophilised: up to 24 months. Reconstituted: 4–6 weeks refrigerated.
- Handling
- Sterile technique throughout.
You might also research
View all →
RTTA
Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.
TRZT
Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.
SMGT
Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.